Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Dermatol ; 17(9): 550-4, 1990 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-2148942

RESUMO

A case of the gold sodium thiomalate (GTM)-induced eruptions with thiomalate (TM) hypersensitivity was reported. A 61-year-old Japanese woman developed lichenoid and seborrheic dermatitis (SD)-like eruptions with alopetia, when the total dosage of GTM administered for rheumatoid arthritis became 110 mg. The eruptions slowly disappeared with pigmentation after discontinuance of the GTM therapy, and the resumption resulted in the development of similar eruptions. She showed a positive reaction to GTM in an intradermal test. She also showed a positive response to TM, which is the thiol carrier of GTM, in the patch test, but a negative one to metallic gold. After administration of auranofin (AF), she also developed the SD-like eruptions with hypersensitivity to metallic gold as well as AF on patch testing, but did not develop the lichenoid ones. Our animal experiments revealed an almost complete cross reaction between GTM and TM, but only a partial one between GTM and aurothioglucose, which have dissmilar structures in the carrier part for gold. Probable roles of hypersensitivity to TM and metallic gold, which are metabolites of GTM, were discussed, respectively, in the genesis of the GTM-induced lichenoid eruptions and the AF-induced SD-like eruptions.


Assuntos
Dermatite Seborreica/induzido quimicamente , Hipersensibilidade a Drogas/etiologia , Tiomalato Sódico de Ouro/efeitos adversos , Líquen Plano/induzido quimicamente , Tiomalatos/efeitos adversos , Animais , Artrite Reumatoide/tratamento farmacológico , Reações Cruzadas , Feminino , Ouro/efeitos adversos , Humanos , Pessoa de Meia-Idade , Testes Cutâneos
2.
Ann Rheum Dis ; 47(3): 224-7, 1988 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-2965555

RESUMO

Ten patients with active rheumatoid arthritis (RA) were entered into a pilot study to evaluate the effectiveness of thiomalic acid as a disease modifying agent and to assess its toxicity. Oral thiomalic acid (100 mg) was given daily for up to six months. Changes in disease activity were recorded monthly and all side effects noted. No patient recorded any improvement in subjective well being, pain score, or duration of early morning stiffness. No significant change occurred in articular index or haemoglobin (Hb); the erythrocyte sedimentation rate (ESR) showed a tendency to increase. Only three patients completed six months' treatment; six withdrew because of toxic reactions (three with rashes and three with severe gastrointestinal upset) and one because of lack of effect. Thiomalic acid alone appears to have no significant antirheumatic activity and is associated with an unacceptably high incidence of adverse reactions.


Assuntos
Artrite Reumatoide/tratamento farmacológico , Tiomalatos/uso terapêutico , Absorção , Administração Oral , Adulto , Toxidermias/etiologia , Feminino , Gastroenteropatias/induzido quimicamente , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Tiomalatos/efeitos adversos , Tiomalatos/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA